JULIPTA Trademark

Trademark Overview


On Tuesday, March 17, 2020, a trademark application was filed for JULIPTA with the United States Patent and Trademark Office. The USPTO has given the JULIPTA trademark a serial number of 88837713. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 12, 2022. This trademark is owned by Allergan Sales, LLC. The JULIPTA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
julipta

General Information


Serial Number88837713
Word MarkJULIPTA
Filing DateTuesday, March 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 12, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 16, 2020

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, March 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Monday, September 12, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 12, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, February 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 3, 2022SOU EXTENSION 3 GRANTED
Thursday, February 3, 2022SOU EXTENSION 3 FILED
Thursday, February 3, 2022TEAS EXTENSION RECEIVED
Wednesday, August 11, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 9, 2021SOU EXTENSION 2 GRANTED
Monday, August 9, 2021SOU EXTENSION 2 FILED
Monday, August 9, 2021TEAS EXTENSION RECEIVED
Wednesday, February 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 8, 2021SOU EXTENSION 1 GRANTED
Monday, February 8, 2021SOU EXTENSION 1 FILED
Monday, February 8, 2021TEAS EXTENSION RECEIVED
Tuesday, August 11, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 16, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 16, 2020PUBLISHED FOR OPPOSITION
Wednesday, June 3, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 3, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 3, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, May 27, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 11, 2020ASSIGNED TO LIE
Saturday, May 2, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 21, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 21, 2020NON-FINAL ACTION E-MAILED
Tuesday, April 21, 2020NON-FINAL ACTION WRITTEN
Tuesday, April 21, 2020ASSIGNED TO EXAMINER
Saturday, March 21, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, March 20, 2020NEW APPLICATION ENTERED IN TRAM